|
DE19921567A1
(de)
*
|
1999-05-11 |
2000-11-16 |
Basf Ag |
Verwendung von Phthalazine-Derivaten
|
|
ES2253353T3
(es)
|
2000-03-08 |
2006-06-01 |
Novo Nordisk A/S |
Reduccion del colesterol serico.
|
|
WO2003031432A1
(en)
|
2001-10-12 |
2003-04-17 |
Novo Nordisk A/S |
Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
|
|
PL370989A1
(en)
|
2001-12-21 |
2005-06-13 |
Novo Nordisk A/S |
Amide derivatives as gk activators
|
|
DE60335359D1
(de)
*
|
2002-04-30 |
2011-01-27 |
Kudos Pharm Ltd |
Phthalazinonderivate
|
|
AU2003243921B2
(en)
|
2002-06-27 |
2009-05-07 |
Novo Nordisk A/S |
Aryl carbonyl derivatives as therapeutic agents
|
|
EP1670815A2
(en)
|
2003-09-30 |
2006-06-21 |
Novo Nordisk A/S |
Melanocortin receptor agonists
|
|
EP2298337B1
(en)
|
2003-12-09 |
2017-02-22 |
Novo Nordisk A/S |
Regulation of food preference using GLP-1 agonists
|
|
BRPI0506662B8
(pt)
|
2004-01-06 |
2021-05-25 |
Novo Nordisk As |
compostos ativadores de glucoquinase
|
|
US20080113944A1
(en)
|
2004-05-04 |
2008-05-15 |
Novo Nordisk A/S |
Novel Indole Derivatives
|
|
EP1758575A1
(en)
|
2004-06-11 |
2007-03-07 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using glp-1 agonists
|
|
US8263551B2
(en)
|
2004-11-22 |
2012-09-11 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations with a protamine salt
|
|
EP1824835A1
(en)
|
2004-12-03 |
2007-08-29 |
Novo Nordisk A/S |
Heteroaromatic glucokinase activators
|
|
MX2007015675A
(es)
|
2005-07-04 |
2008-02-20 |
Novo Nordisk As |
Antagonistas del receptor de histamina h3.
|
|
EP1904467B1
(en)
|
2005-07-14 |
2013-05-01 |
Novo Nordisk A/S |
Urea glucokinase activators
|
|
EP1910317B1
(en)
|
2005-07-20 |
2013-07-03 |
Eli Lilly And Company |
1-amino linked compounds
|
|
ES2393757T3
(es)
|
2005-11-17 |
2012-12-27 |
Eli Lilly & Company |
Antagonistas de receptor de glucagón, preparación y usos terapéuticos
|
|
CN101410385B
(zh)
|
2006-03-28 |
2011-08-24 |
高点制药有限责任公司 |
具有组胺h3受体活性的苯并噻唑类
|
|
EP2402324A1
(en)
|
2006-05-29 |
2012-01-04 |
High Point Pharmaceuticals, LLC |
Benzodioxolylcyclopropylpiperazinylpyridazines
|
|
ATE523497T1
(de)
|
2006-11-15 |
2011-09-15 |
High Point Pharmaceuticals Llc |
Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen
|
|
EP2086951B1
(en)
|
2006-11-15 |
2011-12-21 |
High Point Pharmaceuticals, LLC |
Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
|
|
JP5226008B2
(ja)
|
2007-01-11 |
2013-07-03 |
ノボ・ノルデイスク・エー／エス |
ウレアグルコキナーゼアクチベーター
|
|
BR112012021231A2
(pt)
|
2010-02-26 |
2015-09-08 |
Basf Plant Science Co Gmbh |
método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
|
|
EP2539364A1
(en)
|
2010-02-26 |
2013-01-02 |
Novo Nordisk A/S |
Peptides for treatment of obesity
|
|
EP2552951A1
(en)
|
2010-03-26 |
2013-02-06 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
WO2012104834A1
(en)
|
2011-02-03 |
2012-08-09 |
Pharmedica Ltd. |
New oral dissolving films for insulin administration, for treating diabetes
|
|
RU2013145013A
(ru)
|
2011-03-28 |
2015-05-10 |
Ново Нордиск А/С |
Новые аналоги глюкагона
|
|
AU2012311484B2
(en)
|
2011-09-23 |
2017-04-13 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
EP2986313B1
(en)
|
2013-04-18 |
2019-06-12 |
Novo Nordisk A/S |
Stable, protracted glp-1/glucagon receptor co-agonists for medical use
|
|
US10570184B2
(en)
|
2014-06-04 |
2020-02-25 |
Novo Nordisk A/S |
GLP-1/glucagon receptor co-agonists for medical use
|
|
US20200223889A1
(en)
|
2017-03-15 |
2020-07-16 |
Novo Nordisk A/S |
Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor
|
|
WO2019219714A1
(en)
|
2018-05-15 |
2019-11-21 |
Novo Nordisk A/S |
Compounds capable of binding to melanocortin 4 receptor
|
|
WO2020053414A1
(en)
|
2018-09-14 |
2020-03-19 |
Novo Nordisk A/S |
Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
|